https://doi.org/10.55788/d2344f94
“Compared with a standard Western diet, with a daily dietary sodium intake of about 3,500 mg, a low-sodium diet with an intake of 1,150 mg per day resulted in a systolic BP reduction of 6.7 mmHg,” stated Dr Deepak Gupta (Vanderbilt University Medical Centre, TN, USA) [1]. “Since the publication of these results in 2001, sodium intake has not changed much. There are, however, still gaps in our understanding of the relation between dietary sodium and BP.” For example, Dr Gupta mentioned the association between anti-hypertensive medication and salt sensitivity, and the extent to which lowering dietary sodium affects BP among patients with diabetes.
The CARDIA-SSBP study (NCT04258332) included 228 participants between 50–75 years with systolic BP between 90–160 mmHg and diastolic BP between 50–100 mmHg [1,2]. The investigators used a cross-over design in which participants were randomised to a high-sodium diet, comprising their usual diet plus 2,200 mg sodium per day, or a low-sodium diet (i.e. 500 mg sodium/day). After 7 days, participants switched to the other study group.
After 1 week, participants in the low-sodium group had a mean reduction of 8 mmHg in 24-hour ambulatory systolic BP compared with participants in the high-sodium group (95% CI 4–11 mmHg; P<0.0001). “These results were irrespective of anti-hypertensive medication use or whether participants had controlled or uncontrolled hypertension,” added Dr Gupta. “We did see greater reductions in participants with higher baseline BP and in those with diabetes.” An analysis of the within-individual salt sensitivity showed that systolic BP was reduced with low-sodium intake in 74.4% of the participants, and that systolic BP was increased in 21.6% of the participants taking the low-sodium diet as compared with the high-sodium diet (see Figure).
Figure: 24-hour change in systolic BP calculated as high minus low-sodium diet per individual [2]
BP, blood pressure; SBP systolic blood pressure.
Delta 24-hour BP was calculated as high minus low-sodium diet.
In summary, dietary sodium reductions were associated with reductions in systolic BP, whereas the addition of sodium to a standard Western diet had no clear effect on systolic BP. A meaningful BP reduction was achieved in most individuals in this middle-aged to elderly population within 1 week. “The effect of this intervention is comparable with a first-line anti-hypertensive medication,” according to Dr Gupta.
- Sacks FM, et al. N Engl J Med 2001;344(1):3–10.
- Gupta DK, et al. Effects of dietary sodium on systolic blood pressure in middle-aged individuals: a randomised order cross-over trial. LB04, AHA Scientific Sessions 2023, 11–13 November, Philadelphia, PA, USA.
Copyright ©2024 Medicom Medical Publishers
Posted on
Previous Article
« Intensive BP intervention reduces risk of dementia Next Article
Edoxaban versus warfarin in chronic thromboembolic pulmonary hypertension »
« Intensive BP intervention reduces risk of dementia Next Article
Edoxaban versus warfarin in chronic thromboembolic pulmonary hypertension »
Table of Contents: AHA 2023
Featured articles
Abelacimab substantially lowers bleeding risk compared with rivaroxaban
Hot Topics in CAD/PAD
MINT: Liberal or restrictive transfusion strategy in MI with anaemia?
ORBITA-2 confirms PCI effective for symptom relief in patients with stable angina
Nicotinamide riboside shows promising trend for walking function in PAD
Pemafibrate reduces microvascular complications of PAD and T2D
Dapagliflozin improves cardiometabolic outcomes in myocardial infarction
Optimising Hypertension Outcomes
Edoxaban versus warfarin in chronic thromboembolic pulmonary hypertension
Sodium intake and blood pressure: new insights
Post-partum intervention lowers BP after hypertensive pregnancy
Biannual zilebesiran associated with substantial BP reductions
Future of Lipid-Lowering Therapies
Encouraging data for lepodisiran as Lp(a) lowering therapy
Gene editing may change the treatment landscape of hypercholesterolaemia
REPRIEVE: Mechanisms behind MACE reduction in HIV population on pitavastatin
Recaticimab may offer a solution for uncontrolled hypercholesterolaemia
Atrial Fibrillation and Sudden Cardiac Death
Abelacimab substantially lowers bleeding risk compared with rivaroxaban
Liraglutide may improve post-ablation outcomes in obese patients with AF
Single or dual cardioversion in patients with obesity and AF?
NOAH-AFNET 6: Does the duration of AHRE influence response to edoxaban?
ARTESIA: How useful is anticoagulation in subclinical AF?
Jewel IDE: High compliance rates for novel patch wearable cardioverter defibrillator
Sudden cardiac death in athletes: incidence, causes, and trends over 20 years
Miscellaneous Trials
Successful results for semaglutide in the highly anticipated SELECT trial
Can a walking intervention improve functional status and quality of life in HFrEF?
Head-to-head: Surgical embolectomy versus ultrasound-assisted thrombolysis in high-risk pulmonary embolism
Related Articles
September 8, 2020
COVID-19 not associated with heightened VTE risk after discharge
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com